James Stanker | Chief Financial Officer |
David Young | President and Chief Executive Officer |
François Brisebois | Oppenheimer & Co. Inc. |
Naz Rahman | Maxim Group LLC |
Good afternoon, ladies and gentlemen, and welcome to the Processa Pharmaceuticals Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, James Stanker, Chief Financial Officer of Processa Pharmaceuticals. Sir, the floor is yours.
Thank you, and welcome to Processa’s second quarter 2022 results and clinical pipeline update conference call.